A Phase I First-in-Human Multicenter Randomized Double-Blinded Placebo- Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced Cardiomyopathy
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).
The purpose of this study is to determine the safety of allogeneic MSCs in patients with anthrcycline-induced cardiomyopathy.
- IRB Number: 1510353290 (SURG-NHLBI-FINET-SENECA)
- Research Study Identifier: TX5993
- Principal Investigator: Michael Murphy, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required